drugset / Trial / NCT07714395
Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This study is being done to test the safety of elraglusib when taken once a day and to assess: * How the body processes the drug (pharmacokinetics) * Assess potential effects of the drug on heart rhythm * Find the highest daily dose that can be given without causing side effects
Timeline
- Start
- 2026-10
- Primary completion
- 2029-07
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elraglusib | Small molecule | 125 mg | Oral |
| Subject | Elraglusib | Small molecule | 250 mg | Oral |
| Subject | Elraglusib | Small molecule | 500 mg | Oral |
| Subject | Elraglusib | Small molecule | 750 mg | Oral |